| Year
awarded |
Grant | Author | Location at time of grant | Title/Link to publication |
| 2022 | $60,000 Pfizer |
Dr Sarah Pinto | Melbourne | The Role of Macrophages in Development and Progression of Type 1 Diabetes Mellitus |
| 2022 | $20,000 Pfizer |
Dr Gabby Atlas | Melbourne | Using Whole Genome Sequencing to improve diagnoses for individuals with Differences of Sex Development |
| 2022 | $20,000 Pfizer |
Dr Lara Graves | Sydney | Single cell transcriptomic analysis for identification of recombinant adeno-associated virus serotypes for efficient gene delivery to the adrenal cortex |
| 2022 | $25,000 NovoNordisk |
Dr Kruthika Narayan | Sydney | Role of continuous glucose monitoring in presymptomatic type 1 diabetes detected by general population screening, |
| 2022 | $15,000 Sandoz |
Dr David Cullingford | Perth | Septo-optic Dysplasia: Aetiology, Burden of Disease and Pathophysiology of Hypopituitarism (SODA BUD) |
| 2022 | $25,000 APEG | Yoon Hi Cho | Sydney | Molecular testing in risk stratification of paediatric thyroid nodules of indeterminate pathology |
| 2022 | $20,000 APR | Paul Benetiz-Aguirre | Sydney | Investigating long term outcomes of childhood thyroid cancer |
| 2021 |
$60,000 Pfizer | Dr Karissa Ludwig | Sydney | The diagnosis and characterization of primary bone disorders using urinary stem cells |
| 2021 |
$25,000 NovoNordisk | Dr Tenele Smith | Newcastle | A cross-over, randomised controlled trial examining the efficacy of OptimAPP, a novel smartphone insulin dose calculator for carbohydrate, fat and protein in managing postprandial glycaemia following ‘problematic foods’ in children and young people with type 1 diabetes using insulin pump therapy |
| 2021 |
$25,000 APEG | Dr Erin Sharwood | Queensland | Circadian activity rhythm and hormone function, sleep, fatigue and body composition in early survivors of childhood brain tumours |
| 2021 |
$20,000 Pfizer | Dr Martin de Bock | Christchurch | The effect of non-funded continuous glucose monitoring on health equity in paediatric diabetes in Aotearoa, New Zealand |
| 2021 |
$15,000 Sandoz | Dr Jessica Sandy | Sydney | ‘Multicentre 24-month Outcome Data on real world use of Burosamab: biochemical, functional, radiological outcomes and acceptability study |
| 2020 |
$60,000 Pfizer | Dr Dana Signal | Auckland | Specialized dietary intervention in children with type 1 diabetes |
| 2020 |
$25,000 NovoNordisk | Dr Kerry Buchanan | Brisbane | Markers of endoplasmic reticulum stress in children with recent-onset type 1 diabetes |
| 2020 |
$15,000 Sandoz | Dr Verity Pacey | Sydney | Development of Allied Health Management Guidelines for Children and Adolescents with Osteogenesis Imperfecta |
| 2020 |
$15,000 APEG | Dr Lucinda Lee | Sydney | Generating novel AAV vectors for preclinical modelling of gene therapy treatment for diabetes and other endocrine disorders |
| 2020 |
$10,000 Sanofi | Dr Mercedes Burnside | Christchurch | Addressing the minority Diabetes Divide: A CREATE (Community derived AutomaTEd insulin delivery) Trial Sub-study |
| 2019 |
$60,000 Pfizer | Lara Graves | Sydney | Genome editing as a therapeutic approach to Congenital Adrenal Hyperplasia |
| 2019 |
$25,000 NovoNordisk | Gabby Atlas | Melbourne | Disorders of Sex Development:new approaches to improving diagnosis. |
| 2019 |
$15,000 Sandoz |
Andrew Biggin | Sydney | Understanding the genetic and cellular mechanisms of reduced bone health caused by obesity |
| 2019 |
$15,000 APEG | Mark de Hora | Auckland | Bloodspot Steroid Profiling by Liquid Chromatography Mass Spectrometry-Improving clinical outcomes in congenital adrenal hyperplasia. |
| 2019 | $10,000 Sanofi | Rowen Seckold | Newcastle | Optimising postprandial Glycaemia in children and young people with Type 1 Diabetes using Hybrid Closed Loop insulin delivery: Current challenges and practical clinical solutions. |
| 2018 | $25,000 NovoNordisk | Andrew Biggin | Sydney | Improving height and bone strength in osteogenesis imperfecta using combination growth hormone and bisphosphonate therapy |
| 2018 | $15,000 Sandoz | Yassmin Musthaffa | Brisbane | Insights into growth outcomes in paediatric Turner Syndrome from high-throughput transcriptome and epigenome analyses |
| 2018 | $15,000 APEG | Aveni Haynes | Perth | Using continuous glucose monitoring (CGM) to characterise early dysglycaemia in young children at risk of Type 1 diabetes |
| 2018 | $10,000 Sanofi | Sara Boucher | Dunedin | ‘Flash’ adhesive study: A randomised trial comparing tape and dressings to prolong sensor life in youth using the FreeStyle Libre flash glucose monitoring system |
| 2017 | $25,000 Novo Nordisk | Prudence Lopez | Newcastle | Defining the optimal insulin management for high fat and protein meals in children and young people with Type 1 Diabetes (T1D) using multiple daily insulin injection (MDI) therapy |
| 2017 | $15,000 Sandoz | Matthew Sabin | Melbourne | CardioMetabolicRisk in Youth Obesity: investigating growth trajectories for later disease – The COBRA-CMR study |
| 2017 | $10,000 Sanofi | Benjamin Wheeler | Dunedin | Sleep disturbances in parents of children diagnosed with type 1 diabetes |
| 2017 | $10,000 APEG | Ashleigh Lin | Perth | Characterising fluctuations in stress, anxiety and blood glucose levels in adolescents with type 1 diabetes |
| 2016 | $25,000 Novo Nordisk | Carmel Smart | Newcastle | Establishment of an insulin dosing schedule for high fat, high protein meals in individuals with type 1 diabetes using insulin pump therapy |
| 2016 | $10,000 APEG | Karen Rothacker | Perth | The effect of hyperglycaemia in standard and low insulin states on exercise performance compared to exercise performance in euglycaemia |
| 2016 | $15,000 Sandoz | Rebecca Pelekanos | Brisbane | Developing a multifaceted molecular pipeline to predict good and poor responders to recombinant growth hormone therapy |
| 2015 | $25,000 NovoNordisk | Paul Hofman | Auckland | Does subclinical congenital hypothyroidism cause long term cognitive impairment? |
| 2015 | $15,000 Sandoz | Ian Hughes | Brisbane | Relationships between IGF-1 Values and Growth Hormone Dose and Response to Treatment in Children Treated Under the Australian Growth Hormone Program: An OZGROW Analysis? |
| 2014 | $25,000 NovoNordisk | Tim Jones | Perth | Neurocognitive development of children and adolescents with type 1 diabetes mellitus |
| 2014 | $10,000 Merck Serono | Denise Steers | Wellington | Gender bender, mender or defender? Disorder of sex development –Navigating clinical decision making in New Zealand |
| 2014 | $10,000 SciGen | Stephanie Johnson | Brisbane | To determine the prevalence of MODY in a paediatric diabetes population using Next Generation Sequencing |
| 2014 | $15,000 Eli Lilly |
Tony Huynh | Brisbane | The establishment of HPLC-MS/MS-based dried blood spot 17-OHP target ranges for glucocorticoid dose adjustment in children with Congenital Adrenal Hyperplasia |
| 2013 | $25,000 Novo Nordisk | Carmel Smart | Newcastle | A comparison of three insulin dosage algorithms for meals of variable macronutrient composition on postpranial glucose levels in children with type 1 diabetes |
| 2013 | $10,000 SciGen Grant | Penny Jeffrey | Brisbane | Appetite hormone regulation in Prader-Will Syndrome |
| 2012 | $25,000 Novo Nordisk | Jacqueline Hewitt | Melbourne | Understanding the cause of testicular regression syndrome through whole exome sequencing and gene functional analysis |
| 2012 | $25,000 Novo Nordisk | Yoon Hi Cho | Sydney | Impact of weight gain and insulin resistance on vascular health of adolescents with type 1 diabetes |
| 2012 | $15,000 Eli Lilly |
Fergus Cameron | Melbourne | A randomised controlled trial of the impact of a case management programme as compared with usual care in the transition of young adults with type 1 diabetes mellitus from paediatric to adult services |
| 2012 | $10,000 Ipsen | Maria Craig | Sydney | Enterovirus infection and vitamin D status at the onset of type 1 diabetes |
| 2011 | $15,000 Eli Lilly |
Ahila Ayyavoo | Auckland | The childhood consequences of hyperemesis gravidarum |
| 2011 | $15,000 Merck | Ian Hughes | Brisbane | GH Therapy in Prader-Willi Syndrome |
| 2011 | $10,000 Ipsen | Liz Davis | Perth | Improving insulin sensitivity and vascular function in adolescents with type 2 diabetes using a 12 week supervised exercise intervention: a randomised control trial |
| 2011 | $15,000 Sanofi | Silmara Gusso | Auckland | Does whole body vibration improve body composition and motor function in children with mild to moderate cerebral palsy? |
| 2011 | $25,000 Novo Nordisk | Tim Jones | Perth | Neurocognitive outcomes of children with type 1 diabetes mellitus |
| 2010 | $15,000 Merck Serono | Ann Maguire | Sydney | Gonadal status and hormone replacement in survivors of childhood bone marrow Transplant (no publication written) |
| 2009 | $10,000 Eli Lilly | Margaret Zacharin | Melbourne | Clinical trial of Zoledronic acid (Aclasta) in children and adolescents with Duchenne Muscular Dystrophy |
| 2009 | $15,000 Merck | Peter Simm | Melbourne | The exploration of candidate genes involved in the novel interaction between IGF-1 and FGF2 in an in vitro model of growth plate chondrogenesis |